After-Hours Movers: Horizon Therapeutics Gains on Takeover Talks, CrowdStrike Sinks on EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Jefferies sees up to 90% chance Horizon Therapeutics (HZNP) gets acquired, with $125 base case
December 1, 2022 11:06 AM ESTJefferies analyst Akash Tewari was the latest Wall Street analyst to weigh in on the takeover prospects of Horizon Therapeutics (NASDAQ: HZNP) after the company announced Tuesday that it is in preliminary talks with three large pharmaceutical companies about a potential buyout.
Tewari is positive on the prospects of a deal and sees one happening in the $25-$30 billion range, which he also said does not bake in Tepezza peak sales of $4 billion.
The analyst said the... More
'Compelling value' in Viridian Therapeutics following Horizon Therapeutics acquisition talks
November 30, 2022 10:39 AM ESTShares of Viridian Therapeutics (NASDAQ: VRDN) jumped Wednesday on the back of news on Tuesday evening that Horizon Therapeutics (NASDAQ: HZNP) is in "highly preliminary discussions" with three large pharmaceutical companies.
Horizon Therapeutics shares are up more than 27% during Wednesday's session, while Viridian Therapeutics has also reacted to the news, currently up over 13%.
Within Horizon's portfolio of... More
Horizon Therapeutics seen worth up to $140/share in takeover
November 30, 2022 8:12 AM ESTSeveral Wall Street analysts put pencil to paper after Horizon Therapeutics (NASDAQ: HZNP) said Tuesday evening that it was in "highly preliminary" takeover talks with Amgen Inc. (NYSE: AMGN), Janssen Global Services, LLC (NYSE: JNJ), and Sanofi (NYSE: SNY). A deal price as high as $140 per share was the high watermark discussed by at least two analysts.
Cowen analyst Ken Cacciatore said that given their belief that Tepezza's previous pause was... More
